key: cord-1053202-d8uasw43
authors: Serei, Virian D.; Cristelli, Ryan; Joho, Kim; Salaru, Gratian; Kirn, Thomas; Carayannopoulous, Mary O.; Uprety, Priyanka
title: Comparison of Abbott ID NOW COVID-19 rapid molecular assay to Cepheid Xpert Xpress SARS-CoV-2 assay in dry nasal swabs
date: 2020-09-16
journal: Diagn Microbiol Infect Dis
DOI: 10.1016/j.diagmicrobio.2020.115208
sha: d498e3aa90c4bafa1a35bd315effd05a9ca66023
doc_id: 1053202
cord_uid: d8uasw43

nan

In December 2019, a novel coronavirus, SARS-CoV-2, causing severe respiratory symptoms (COVID-19) emerged as a global pandemic [1] . The Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) allowing the use of numerous molecular assays for in vitro diagnostics (IVD) in order to meet COVID-19 testing demands. However, the analytical performance characteristics of authorized assays have not been well studied. The Abbott ID NOW COVID-19 molecular point-of-care (POC) test is intended to provide COVID-19 results within minutes via isothermal amplification. In comparison, other rapid molecular platforms are RT-PCR based and may take anywhere from 1 to 3 hours to perform [2] .

In an effort to find a molecular platform that could provide accurate results within a short time (13 minutes or less) compared to our standard of care rapid molecular platform Cepheid Xpert® Xpress SARS-CoV-2 assay (45 minutes or less), a correlation study was performed using nasal swabs from symptomatic patients in the Emergency Department (ED) at Robert Wood Johnson University Hospital (RWJUH), New Brunswick, NJ. This study was approved by the Rutgers Institutional Review Board (IRB). Briefly, ED nursing staff collected 105 paired nasal swabs from adult (>18 years), non-pregnant patients under investigation for COVID-19. Two nasal swabs were collected, one swab was placed in viral transport media (VTM) for routine COVID-19 testing using the Cepheid Xpert® Xpress SARS-CoV-2 assay (Cepheid, Sunnyvale, CA) performed on the GeneXpert Infinity platform (Cepheid, Sunnyvale, CA), which is a real-time PCR test that detects the N2 and E SARS-CoV-2 nucleic acids. A second "dry" nasal swab was collected without elution in VTM, placed directly in the original package, held in a refrigerator (2-8C) for up to 12 hours from time of sample collection, and directly analyzed 

Timeline of WHO's response to COVID-19

Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection

Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2

Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients

Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2

Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution